Human embryos repair single-strand DNA damage effectively during early development, but handle double-strand breaks with significantly less reliability, according to a study published in the journal Nature. Led by first author Štěpán Jeřábek of Columbia University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), the research provides a detailed look at how embryonic DNA responds to distinct types of gene editing.
How Early Human Embryos Respond to DNA Damage
Treating inherited diseases is one of the greatest challenges in modern medicine, with targeted gene corrections at the earliest stages of embryonic development offering a potential path to prevent these conditions from passing to future generations. However, safety depends on how human embryos repair DNA damage caused during editing. According to Jeřábek, the study delivers the first detailed comparison of how embryos react to two different classes of genetic injury. The findings reveal that while single-strand DNA damage is repaired effectively, double-strand breaks prove notably less reliable during early development.
Comparing CRISPR-Cas9 and Base Editing in Embryonic Cells
To evaluate these distinct repair pathways, researchers introduced targeted modifications into two well-studied genes utilizing separate genome-editing tools, as detailed in the Nature study. Using CRISPR-Cas9, the team introduced double-strand breaks into embryonic DNA. In contrast, base editing produced only a single-strand nick. By analyzing the resulting cellular responses, the scientists mapped out how repair mechanisms diverge based on the specific type of DNA disruption applied, according to the published findings.
Did you know? Researchers successfully isolated stem cells from edited six-day-old embryos during the study. These stem cells supplied the genetic material needed for deep analyses of gene-editing consequences across subsequent generations of cells.
Safety Questions and Clinical Hurdles Ahead
While base editing demonstrated a significant improvement in precision over CRISPR-Cas9 regarding DNA repair outcomes, researchers emphasize that significant safety questions remain unresolved before clinical applications can be considered. Jeřábek stated that the primary objective of the basic research was to understand natural DNA repair mechanisms during early human development rather than immediately build a method for genetically modifying human embryos. Conducted in the laboratory of Dieter Egli under the oversight of Columbia University’s ethics committee, the project has already drawn widespread international attention, including coverage by The New York Times.
Jan Konvalinka, director of IOCB Prague—which contributed scientists Iva Pichová and Michal Doležal to the project—noted the critical value of such foundational science. Konvalinka stated that the ongoing ethical debate surrounding these studies is both legitimate and necessary, as basic research expands knowledge boundaries while clarifying the possibilities and limitations of current technologies.
Frequently Asked Questions
What is the main difference between CRISPR-Cas9 and base editing in embryos?
According to the published study, CRISPR-Cas9 introduces double-strand breaks into embryonic DNA, whereas base editing produces only a single-strand nick, leading to different repair reliability in early human embryos.
Why are early embryo DNA repair mechanisms difficult to study?
Little has historically been known about how DNA repair operates during the earliest stages of human development, though isolating stem cells from six-day-old edited embryos now allows researchers to study these genetic effects in greater depth.